Latest Clinical Expansion News

Amplia Therapeutics has teamed up with Eli Lilly to test its FAK inhibitor narmafotinib alongside Lilly’s KRAS G12C inhibitor olomorasib in advanced non-small cell lung cancer, marking a strategic expansion beyond pancreatic and ovarian cancers.

Emyria has expanded its Empax clinic network across four states, reporting a 210% revenue increase in FY26 and early clinical success in treatment-resistant depression.

Lumos Diagnostics has received a A$709,837 cash refund from the Australian Government’s R&D Tax Incentive, bolstering its investment in proprietary point-of-care diagnostic technologies.

Emyria’s new treatment-resistant depression program shows statistically significant symptom improvements in a small initial cohort, expanding its mental health therapy offerings beyond PTSD.

Emyria Limited is progressing its national network of psychedelic-assisted therapy clinics, reporting durable patient outcomes, expanding funding sources, and benefiting from regulatory changes that broaden therapist eligibility.

Imugene has dosed the first patient in a new cohort combining its azer-cel CAR T therapy with BTK inhibitors, targeting patients with B-cell malignancies who failed prior BTKi treatment. This move broadens the trial’s scope and tackles a significant unmet need in blood cancer therapy.

EMVision's First Responder Brain Scanner has proven its operational feasibility in aeromedical settings with the Royal Flying Doctor Service, de-risking rural stroke diagnosis and supporting progression to commercial production.

BCAL Diagnostics has embedded referral forms for its early cancer detection tests into clinical software used by 97% of Australian GPs, launched a telehealth platform, and opened a Sydney clinic, gearing up for a multi-cancer test launch in June 2026.

Emyria has launched its first Empax clinic in Victoria on schedule, establishing a new clinical hub with trained staff and dual reimbursement pathways to support growth.

Emyria Limited reported $1.2 million in revenue for the March quarter, driven by insurer-funded clinics and strong clinical outcomes in PTSD treatment. The company is advancing its national clinic rollout, including new sites in Victoria and New South Wales, while launching a global partnership program targeting international drug sponsors.

Epsilon Healthcare has achieved its highest quarterly receipts ever with $3.14 million in Q1 2026, driven by strong expansion across contract manufacturing, clinics, and pharmacy operations.

Emyria reported $1.2 million revenue for Q1 2026 driven by insurer-funded clinics and expanded its Empax network across multiple states. It launched a Global Partnership Program targeting international drug sponsors, leveraging its clinical infrastructure amid growing global interest in psychedelic therapies.